Drug Trial Radar · NCT03205995
Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome
Last checked: Nov 20, 2026Latest source record: Dec 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
6
Actual
Start
May 2, 2018
Primary completion
Feb 2, 2021
Study completion Feb 2, 2021
Sponsor
- Lead sponsor
- Omeros CorporationIndustry
- Sponsor type
- Industry
- First posted
- Jul 2, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the platelet count change from baseline and safety of OMS721 (narsoplimab) in adults and adolescents with atypical hemolytic uremic syndrome (aHUS). The study will also evaluate pharmacokinetics (PK), pharmacodynamics (PD), and anti-drug antibody response (ADA).
Conditions
- Thrombotic Microangiopathies
- Atypical Hemolytic Uremic Syndrome
Interventions
OMS721 (narsoplimab)Biological
Intravenous loading dose followed by daily subcutaneous injections
Primary outcomes
What the sponsor says the trial is designed to measure.
- Platelet Count (10^9 Platelets/L) Change From Baseline at Week 26Time frame: Week 26
Locations
4 sites in 4 countries. Site status is shown where the registry gives one.
Omeros Investigational Site
Chicago, Illinois
Omeros Investigational Site
Vilnius, Lithuania
Omeros Investigational Site
Lodz, Poland
Omeros Investigational Site
New Taipei City, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.